SEC Form 4 · accession 0001209191-17-046339
Minerva Neurosciences, Inc. · NERV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nico Vandervelpen
Director
Period of report
Jul 24, 2017
Accepted (ET)
Jul 26, 2017 · 5:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001598646
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.71 | Jul 24, 2017 | D | 25,000 | D | — | Dec 3, 2025 | Common Stock | 25,000 | 0 | D |
| Stock Option (Right to Buy)F1 | $4.71 | Jul 24, 2017 | A | 25,000 | A | — | Jul 24, 2018 | Common Stock | 25,000 | 25,000 | D |
| Stock Option (Right to Buy)F2 | $10.20 | Jul 24, 2017 | D | 12,500 | D | — | Jun 15, 2026 | Common Stock | 12,500 | 0 | D |
| Stock Option (Right to Buy)F2 | $10.20 | Jul 24, 2017 | A | 12,500 | A | — | Jul 24, 2018 | Common Stock | 12,500 | 12,500 | D |
| Stock Option (Right to Buy)F3 | $10.00 | Jul 24, 2017 | D | 12,500 | D | — | May 31, 2027 | Common Stock | 12,500 | 0 | D |
| Stock Option (Right to Buy)F3 | $10.00 | Jul 24, 2017 | A | 12,500 | A | — | Jul 24, 2018 | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 4, 2015 and provides for vesting quarterly over 3 years beginning on December 4, 2015.
- F2The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 16, 2016 and provides for vesting in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 16, 2016 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
- F3The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 1, 2017 and provides for vesting in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 1, 2017 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.